3-deazaneplanocin has been researched along with Cancer of Lung in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, C; Chen, J; Gong, H; Li, W; Li, Y; Liu, C; Liu, H; Liu, M; Shi, R; Yuan, Y; Zhang, H; Zhang, Z | 1 |
| Amin, SG; Belinsky, SA; Desai, DH; Do, K; Filipczak, PT; Hutt, JA; Juri, D; Picchi, MA; Tellez, CS | 1 |
| Kim, KC; Lee, JK | 1 |
| Behrens, C; Coombes, KR; Girard, L; Heymach, J; Hong, WK; Lee, JJ; Lin, HY; Minna, JD; Nilsson, MB; Riquelme, E; Simon, G; Suraokar, M; Wang, J; Wistuba, II | 1 |
| Dosaka-Akita, H; Kikuchi, J; Kinoshita, I; Nishimura, M; Oizumi, S; Sakakibara-Konishi, J; Shimizu, Y; Takashina, T | 1 |
| Dosaka-Akita, H; Kikuchi, E; Kikuchi, J; Kinoshita, I; Marquez, VE; Nishimura, M; Oizumi, S; Sakakibara-Konishi, J; Shimizu, Y; Takashina, T | 1 |
6 other study(ies) available for 3-deazaneplanocin and Cancer of Lung
| Article | Year |
|---|---|
EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Topics: Adenosine; Adult; Aged; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Protein Kinase Inhibitors; Pyridones; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction | 2020 |
Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
Topics: Adenosine; Adenosylhomocysteinase; Animals; Benzamides; Biphenyl Compounds; Cell Proliferation; Chromatin Assembly and Disassembly; CpG Islands; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; Epithelial Cells; Female; Histone Code; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; Humans; Lung Neoplasms; Mice; Morpholines; Neoplasms; Phenotype; Pyridones; Transcriptome | 2021 |
DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
Topics: Adenosine; Adenosylhomocysteinase; Cell Death; Cell Line, Tumor; Down-Regulation; Enzyme Inhibitors; Histone-Lysine N-Methyltransferase; Histones; Humans; Lung; Lung Neoplasms; Methylation; Promoter Regions, Genetic; Protein Methyltransferases | 2013 |
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adenosine; Animals; Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Enhancer of Zeste Homolog 2 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mice, Nude; MicroRNAs; Molecular Targeted Therapy; Polycomb Repressive Complex 2; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2014 |
Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Topics: Acetylation; Adenosine; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclin A; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Hydroxamic Acids; Lung Neoplasms; Methylation; Mice; Mice, Inbred BALB C; Mutation; Phosphorylation; Polycomb Repressive Complex 2; Signal Transduction; Vorinostat; Xenograft Model Antitumor Assays | 2016 |
Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Topics: Adenosine; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; G1 Phase Cell Cycle Checkpoints; Gene Expression; Gene Knockdown Techniques; Histones; Humans; Inhibitory Concentration 50; Lung Neoplasms; Methylation; Neoplasm Proteins; Polycomb Repressive Complex 2; Protein Processing, Post-Translational; RNA Interference; Transcription Factors | 2012 |